This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
After Plunging 19.7% in 4 Weeks, Here's Why the Trend Might Reverse for Allena Pharmaceuticals, Inc. (ALNA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Allena Pharmaceuticals, Inc. (ALNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Allena Pharmaceuticals, Inc. (ALNA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Allena Pharmaceuticals, Inc. (ALNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Allena Pharmaceuticals (ALNA) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Allena Pharmaceuticals (ALNA) has been struggling lately, but the selling pressure may be coming to an end soon.
Moving Average Crossover Alert: Allena Pharmaceuticals (ALNA)
by Zacks Equity Research
Allena Pharmaceuticals (ALNA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Allena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALNA) Outperforming Other Medical Stocks This Year?
CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.
Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
Celldex Initiates Early-Stage Antibody Study for Skin Disorder
by Zacks Equity Research
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
What Makes Allena Pharmaceuticals, Inc. (ALNA) a New Buy Stock
by Zacks Equity Research
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allena Pharmaceuticals, Inc. (ALNA) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?
by Zacks Equity Research
Within the Health Care Benefits segment, CVS Health (CVS) expects the government programs to go from strength to strength on the back of Medicare growth and major Medicaid wins.
Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?
by Zacks Equity Research
Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) projects operating income within $460-$465 million for the second quarter.
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.
AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical Distribution and higher revenues are likely to aid AmerisourceBergen (ABC) in Q3 earnings.
Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.
Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Masimo's (MASI) recent developments likely to show on second-quarter results.
What's in the Offing for DexCom's (DXCM) Earnings in Q2?
by Zacks Equity Research
Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.
All You Need to Know About Allena Pharmaceuticals, Inc. (ALNA) Rating Upgrade to Buy
by Zacks Equity Research
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allena Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Allena Pharmaceuticals has been on a bit of a cold streak lately but there might be light at the end of the tunnel for this overlooked stock.